Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with
Go back to Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with| (NASDAQ: ZEAL) | Delayed: 17.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.59 | 52 Week High | $ | |||
| Open | $1.35 | 52 Week Low | $ | |||
| Day High | $17.59 | P/E | N/A | |||
| Day Low | $17.59 | EPS | $ | |||
| Volume | 15,962 | |||||
